Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms
- PMID: 37161628
- DOI: 10.1111/apt.17462
Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms
Comment in
-
Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply.Aliment Pharmacol Ther. 2023 Jun;57(11):1337-1338. doi: 10.1111/apt.17496. Aliment Pharmacol Ther. 2023. PMID: 37161629 No abstract available.
Comment on
-
Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.Aliment Pharmacol Ther. 2023 Jun;57(11):1258-1271. doi: 10.1111/apt.17426. Epub 2023 Mar 3. Aliment Pharmacol Ther. 2023. PMID: 36866724
References
REFERENCES
-
- Zikos TA, Nguyen L, Kamal A, Fernandez-Becker N, Regalia K, Nandwani M, et al. Marijuana, ondansetron, and promethazine are perceived as most effective treatments for gastrointestinal nausea. Dig Dis Sci. 2020;65:3280-6.
-
- Zofran (ondansetron) label. U.S. Food and Drug Administration.
-
- Tack J, Janssen P, Wouters M, Boeckxstaens G. Targeting serotonin synthesis to treat irritable bowel syndrome. Gastroenterology. 2011;141:420-2.
-
- Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, et al. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial. Aliment Pharmacol Ther. 2023;57:1258-71.
-
- Yu V, Ballou S, Hassan R, Singh P, Shah E, Rangan V, et al. Abdominal pain and depression, not bowel habits, predict health care utilization in patients with functional bowel disorders. Am J Gastroenterol. 2021;116:1720-6.